CA2678131A1 - Colonic delivery using zn/pectin beads with a eudragit coating. - Google Patents

Colonic delivery using zn/pectin beads with a eudragit coating. Download PDF

Info

Publication number
CA2678131A1
CA2678131A1 CA002678131A CA2678131A CA2678131A1 CA 2678131 A1 CA2678131 A1 CA 2678131A1 CA 002678131 A CA002678131 A CA 002678131A CA 2678131 A CA2678131 A CA 2678131A CA 2678131 A1 CA2678131 A1 CA 2678131A1
Authority
CA
Canada
Prior art keywords
human
drug delivery
agents
agent
delivery system
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002678131A
Other languages
English (en)
French (fr)
Inventor
Antoine Andremont
Helene-Celine Huguet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Da Volterra SAS
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2678131A1 publication Critical patent/CA2678131A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5026Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13Cyclosporins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/191Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/465Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/50Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10Laxatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002678131A 2006-11-17 2007-11-16 Colonic delivery using zn/pectin beads with a eudragit coating. Abandoned CA2678131A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US85960006P 2006-11-17 2006-11-17
US85959906P 2006-11-17 2006-11-17
US60/859,599 2006-11-17
US60/859,600 2006-11-17
PCT/EP2007/062475 WO2008059062A1 (en) 2006-11-17 2007-11-16 Colonic delivery using zn/pectin beads with a eudragit coating.

Publications (1)

Publication Number Publication Date
CA2678131A1 true CA2678131A1 (en) 2008-05-22

Family

ID=39181811

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002678131A Abandoned CA2678131A1 (en) 2006-11-17 2007-11-16 Colonic delivery using zn/pectin beads with a eudragit coating.

Country Status (7)

Country Link
EP (1) EP2081557A1 (zh)
JP (1) JP2010510196A (zh)
CN (1) CN101795675A (zh)
AU (1) AU2007321111A1 (zh)
BR (1) BRPI0719319A2 (zh)
CA (1) CA2678131A1 (zh)
WO (1) WO2008059062A1 (zh)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010538987A (ja) * 2007-09-11 2010-12-16 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト 治療剤としてのタフトシンの使用
WO2009033707A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
US20100204145A1 (en) * 2007-09-11 2010-08-12 Dorian Bevec Use of a peptide as a therapeutic agent
CZ302789B6 (cs) 2009-11-25 2011-11-09 Zentiva, K. S. Zpusob zvýšení rozpustnosti farmaceuticky aktivních látek a cílený (kontrolovaný) transport do streva
US9572856B2 (en) 2009-12-16 2017-02-21 The George Washington University a Congressionally Chartered Not-for-Profit Corporation Method of treating low blood pressure
CA2790811C (en) 2010-02-23 2017-12-05 Da Volterra Formulations for oral delivery of adsorbents in the gut
US20130089585A1 (en) * 2010-04-08 2013-04-11 Merz Pharma Gmbh & Co., Kgaa Filler comprising beads
GB201202433D0 (en) 2012-02-13 2012-03-28 Diurnal Ltd Controlled drug release
EP2968187A4 (en) * 2013-03-14 2016-08-17 Therabiome Llc TARGETED ADMINISTRATION OF PROBIOTIC ORGANISMS AND / OR THERAPEUTIC AGENTS IN THE GASTROINTESTINAL TRACT
EP3858437A1 (en) * 2013-04-26 2021-08-04 La Jolla Pharma, LLC Compositions and methods for treating renal failure
WO2015066212A2 (en) * 2013-10-31 2015-05-07 University Of Hawaii Calpain inhibitors for treatment of inflammatory bowel disease and colorectal cancer
KR102399383B1 (ko) 2013-12-18 2022-05-19 더 조지 워싱턴 유니버시티 저혈압의 치료를 위한 안지오텐신 ii 단독 또는 조합
US10206884B2 (en) 2013-12-20 2019-02-19 Fresenius Kabi Deutschland Gmbh Microcapsules with polymeric coating comprising a lipid and an active agent
HUE053962T2 (hu) * 2014-09-11 2021-08-30 Gelita Ag Zselatin/pektin részecskék
US20160158174A1 (en) * 2014-12-09 2016-06-09 Intercontinental Great Brands Llc Enteric-Coated Functional Food Ingredients And Methods For Making The Enteric-Coated Functional Food Ingredients
BR112018013847A2 (pt) 2016-01-07 2018-12-18 La Jolla Pharma Co métodos para administrar a angiotensina ii
CN109562147B (zh) * 2016-06-28 2023-09-01 特里瓦生物制剂有限公司 保护微生物组免受口服抗生素
WO2018090266A1 (zh) * 2016-11-17 2018-05-24 上海交通大学医学院 口服结肠靶向的递送系统及其制备方法和应用
DE102017000896A1 (de) * 2017-02-01 2018-08-02 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Selektives Freisetzungssystem für Tumortherapeutika und Tumordiagnostika sowie Biosensor für Tumorgewebe
WO2018191678A1 (en) 2017-04-14 2018-10-18 La Jolla Pharmaceutical Company Methods for administering angiotensin ii

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840332A (en) * 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
RU2375047C2 (ru) * 2004-03-26 2009-12-10 Лек Фармасьютиклз Д.Д. Фармацевтическая лекарственная форма, устойчивая к действию желудочного сока, включающая n-(2-(2-фталимидоэтокси)ацетил)-l-аланил-d-глутаминовую кислоту (lk 423)
PL1883396T3 (pl) * 2005-05-18 2014-03-31 Da Volterra Dostarczanie adsorbentów do okrężnicy

Also Published As

Publication number Publication date
CN101795675A (zh) 2010-08-04
EP2081557A1 (en) 2009-07-29
WO2008059062A1 (en) 2008-05-22
JP2010510196A (ja) 2010-04-02
AU2007321111A1 (en) 2008-05-22
BRPI0719319A2 (pt) 2014-02-04

Similar Documents

Publication Publication Date Title
CA2678131A1 (en) Colonic delivery using zn/pectin beads with a eudragit coating.
US20080124279A1 (en) Colonic delivery using Zn/pectin beads with a Eudragit coating
US20080317666A1 (en) Colonic Delivery of Active Agents
KR101080577B1 (ko) 활성성분의 결장 표적화 전달을 위한 제제
KR0157280B1 (ko) 하부소화관 방출성의 경구의약제제
Prasanth et al. Colon specific drug delivery systems: a review on various pharmaceutical approaches
JP2002521346A (ja) 多糖類を利用した大腸選択性薬物伝達組成物および医薬製剤
KR20190127984A (ko) 지연 방출형 약물 제형
RU2282462C2 (ru) Композиции и способы улучшения перорального всасывания противомикробных средств
JP2013525351A (ja) ナノ粒子の医薬組成物
Gupta A review article on colonic targeted drug delivery system
US8273376B2 (en) Colonic delivery of metallo-dependent enzymes
US20220202721A1 (en) Articles and methods for administration of therapeutic agents
EP3737750B1 (en) Alkaline phosphatase agents for treatment of neurodevelopmental disorders
Patel et al. Colon targeted drug delivery: Approaches and newer technology
US20220257726A1 (en) Intestinal alkaline phosphatase-based treatments of metabolic disorders
FR2843301A1 (fr) Forme galenique pour la delivrance colique de principes actifs
AU2002300676B2 (en) A method for the treatment of diarrheal disease and for eliminating particular bacterial populations from the colon
Goracinova et al. Drug targeting in IBD treatment–Existing and new approaches

Legal Events

Date Code Title Description
FZDE Dead